Researchers compared rates of symptoms prior to infection and rate of long-term symptoms post-infection in three groups. The study population included: COVID-19 patients between Jan. 1, 2020, and July 1, 2021; non-COVID, non-influenza viral pneumonia patients between Jan. 1, 2018, and July 1, 2019; and influenza patients between Jan. 1, 2018, and July 1, 2019.
Three key findings:
- An additional 3.7 percent of patients reported new long-term symptoms after COVID-19 and pneumonia infections.
- An additional 1.5 percent of influenza patients reported new long-term symptoms.
- Among hospitalized patients, an additional 5.4 percent of COVID-19 patients, 6.4 percent of influenza patients and 5.2 percent of viral pneumonia patients sought treatment for long-term symptoms following infection.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
